From a previously established cohort of 177 patients with BD uveitis treated with anti-TNF [26] and from a series of 80 refractory patients with immune-mediated inflammatory disease (IMID) uveitis treated with CZP [29], we selected those presenting CME-related BD uveitis at baseline time (25, 15 and 10 patients treated with ADA, IFX and CZP, respectively). This evidence concerns the gene TNF and Behcet disease.